The sleeve is full.Very interesting. Thanks.. I would say something serious is up that sleeve for many reasons........ I can't believe new leadership would begin their tenure with granting generous options to the CFO unless significant improvements have been made..the boards timing to to fill the CEO seat...Very early debenture payment to become debt free.......and the many items included in the recent quarterly update....no matter how small the order ,to be making deliveries of "advanced API's to traditional pharma" .......this is something I just can't shake outta my mind....that statement is loaded....It's extent will be forthcoming by next earnings call at the latest...this company has changed...It's emanating with confidence...not at the mercy of capital markets so more concerned about producing results culminating from years of hard work...this is my honest opinion.